Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot Study

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Diabetic Peripheral Neuropathic Pain (DPN), Diabetic Neuropathies

In brief

The "Cannabidiol for the Treatment of Diabetic Peripheral Neuropathy: Pilot study (CBD-DPN1)" is a double-blinded, placebo-controlled, crossover pilot study evaluating the efficacy of Cannabidiol (CBD) and full-spectrum CBD (fsCBD) tinctures in treating Diabetic Peripheral Neuropathy (DPN)-associated pain. DPN is a common, highly distressing complication of diabetes, characterized by chronic pain and loss of sensory function, for which currently available treatments primarily offer only symptomatic relief. CBD and fsCBD are being investigated for their potential neuroprotective and analgesic effects by regulating inflammation and oxidative stress. The study aims to recruit 12 to 20 adult participants who have mild to moderate DPN. Subjects will receive either an active treatment (CBD isolate or fsCBD in MCT oil, dosed at 50 mg twice daily for a total of 100 mg daily) or a placebo during two sequential 6-week phases. The overall objective of this pilot phase is primarily methodological: to test and refine the clinical protocol, assess patient compliance and acceptability of the CBD formulations, and generate sufficient data to calculate the necessary sample size for a larger, definitive study. Efficacy will be measured using objective and subjective metrics, including DPN severity (DN4 Assessment Tool and DPNCheck™ for nerve conduction velocity) and pain level (PainDetect Questionnaire). Secondary outcomes include evaluating mood (HADS), sleep quality (MOS Sleep Scale), and quality of life (EQ-5D-5L).

Key facts

Study ID: NCT07298408
Run by: Florida A&M University
People needed: 20
Starts: 2026-04-02
Expected to finish: 2027-06-30
Last updated by the study team: 2026-04-29

Who can join

Age: 40 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Adult aged 40 to 70 years
Diagnosis of Type 2 Diabetes
Ambulatory and independently living adult
Minimum body weight of 50 kg (to ensure daily dose ≤2 mg/kg)
Physical exam completed within the previous 6 months
Liver Function Studies (ALT and AST) completed within the previous six months showing normal values
If NAFLD is present, ALT and AST levels are ≤2 times the Upper Limit of Normal (ULN)
DN4 questionnaire results indicate mild to moderate DPN
Nerve Conduction Test (NCT) confirms at least mild DPN
Signed ICF/Screening Consent
Able to complete required questionnaires (adequate vision)

You may not qualify if…

High-risk or severely ill individuals (e.g., high risk for general anesthesia, significant limitations due to heart/lung disease, ascites, renal failure, loss of limbs from diabetic complications)
Uncontrolled or severe cardiovascular disease (e.g., unstable angina, uncontrolled heart failure, recent myocardial infarction)
History of atrial fibrillation, dysrhythmias, MI within the previous 2 years, or stroke
Severe respiratory illness (e.g., uncontrolled asthma, COPD with frequent exacerbations, oxygen dependence)
Severe or uncontrolled liver disease (e.g., cirrhosis, active viral hepatitis A, B, or C, autoimmune hepatitis, uncontrolled primary biliary cholangitis or primary sclerosing cholangitis)
Elevation of liver enzymes (ALT or AST) exceeding 2 times the ULN, or bilirubin exceeding the ULN
Severe or uncontrolled kidney disease (e.g., end-stage renal disease requiring dialysis, uncontrolled nephrotic syndrome)
History of malignancy within the past 5 years (excluding certain low-risk non-melanoma skin cancers)
History of a seizure disorder
Blindness (poor vision preventing questionnaire completion)
Known allergy or previous adverse reaction to any ingredient, including natural strawberry flavoring
Reproductive Health (Women Only)
Currently pregnant or lactating
Women who can get pregnant who are not using acceptable methods of birth control
Current uncontrolled mental health conditions (e.g., major depressive episode with active suicidal ideation, bipolar disorder with current manic/hypomanic episode, or psychosis)
Diagnosis of a major depressive episode with active suicidal ideation and/or a plan to attempt suicide within the previous 5 years
Attempted suicide in the last 10 years
C-SSRS Suicide Ideation Subscore ≥5 at study onset
HADS-D score ≥15 at study onset
Used cannabis products in the past 30 days
Current use or history of illicit drug use or misuse of prescription medications within the previous 5 years
Heavy drinking (≥8 drinks/week for women; ≥15 drinks/week for men)
Taking medications that are known to cross-reacting with CBD or Cannabiods

Where it is running

the FSU TMH Family Practice Residency Program — Tallahassee, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.